Principal Investigator: Ali Khatibi
Co-Investigators: Abhirup Ghosh, Jack Rogers, Rachel Upthegrove and Saiju Jacob
Centre Fellow: Yingjing Feng
Artist: Christie Swallow
Psychotic disorders are costly conditions, with billions spent on healthcare and over £18 billion annual economic impact in the UK. Early diagnosis improves recovery and reduces burden, but psychosis patients present diverse symptoms, characteristics, and treatment responses. Classifying patients into subgroups enables identifying tailored treatment options to improve outcomes.
This project aims to predict which high-risk individuals will develop psychosis by analysing blood biomarkers combined with brain imaging data. We also seek to understand factors contributing to variability among psychosis patients to facilitate earlier intervention and personalised treatments.
Our analysis integrates inflammatory biomarker measurements and brain MRI scans. Advanced statistical techniques will study connections between biomarkers and brain functioning. AI and computer science methods will create predictive models classifying patients based on biomarker levels and brain imaging features. This classification can guide understanding of which treatments are most effective for different subgroups.
This novel approach offers a personalised, proactive strategy for early psychosis intervention by accounting for disorder heterogeneity. Integrating blood biomarkers with brain imaging has the potential to revolutionise treatment outcomes through tailored care from the earliest stages.